{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/prescribing-information/beta-2-agonists/","result":{"pageContext":{"chapter":{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists","depth":2,"htmlHeader":"<!-- begin field a41ff3c5-384c-4317-8231-9afdbd53dbfe --><h2>Beta-2 agonists</h2><!-- end field a41ff3c5-384c-4317-8231-9afdbd53dbfe -->","summary":"","htmlStringContent":"<!-- begin item a11e3199-2c29-478d-a56e-bea32d5c5fbe --><!-- begin field d1693c13-3914-432d-b6f5-d100878020e1 --><ul><li><strong>Beta-2 agonists act directly on beta-2 receptors, causing smooth muscle relaxation and dilatation of the airways</strong>.<ul><li><strong>Short-acting beta-2 agonists (SABAs)</strong> such as salbutamol and terbutaline are used for immediate relief of symptoms and have a rapid onset of action (15 minutes) — effects last for 4–6 hours.</li><li><strong>Long-acting beta-2 agonists (LABAs)</strong> such as salmeterol and formoterol, have a duration of action of 12 or more hours. Indacaterol and olodaterol are once daily LABAs licensed for use in COPD in adults; they are not indicated for the relief of acute bronchospasm. Vilanterol is a long-acting beta-2 agonist available only in a combination inhaler with fluticasone furoate or/and with umeclidinium.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>]</p><!-- end field d1693c13-3914-432d-b6f5-d100878020e1 --><!-- end item a11e3199-2c29-478d-a56e-bea32d5c5fbe -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"43540d53-15cb-569e-9001-53259bb7e74c","slug":"dose-of-short-acting","fullItemName":"Dose of short-acting","depth":3,"htmlHeader":"<!-- begin field 9b062680-6344-4511-be67-f9e98baab1f5 --><h3>Which short-acting beta-2 agonists are available for COPD, and what dose should I prescribe?</h3><!-- end field 9b062680-6344-4511-be67-f9e98baab1f5 -->","summary":"","htmlStringContent":"<!-- begin item e6ccbd5d-2727-4a58-b5d4-0845d2f90518 --><!-- begin field 629e5d51-1c9c-4017-8b4a-cbdfb4ac559c --><ul><li><strong>Salbutamol (off-label use)</strong><ul><li>Aerosol inhalation — 100 micrograms to 200 micrograms (1–2 puffs) up to four times daily.</li><li>Dry powder inhalation — 200 micrograms to 400 micrograms up to four times daily.</li><li>Nebulized solution — 2.5 mg to 5 mg, up to four times daily.<ul><li>If dilution is necessary, a suitable volume of sterile sodium chloride 0.9% should be used.</li></ul></li><li>Recommended doses may vary slightly for the different brands available. Doses for specific brands can be found in the BNF and the manufacturers' Summaries of Product Characteristics.</li></ul></li><li><strong>Terbutaline sulfate (off-label use)</strong><ul><li>Dry powder inhalation — 500 micrograms (1 inhalation) up to four times daily.</li><li>Nebulized solution — 5 mg to 10 mg two to four times daily.</li></ul></li><li><strong>Combination product</strong><ul><li>Salbutamol 2.5 mg plus ipratropium bromide 500 micrograms — 2.5 mL (one vial) three or four times daily.</li><li>Licensed for the treatment of bronchospasm in people with COPD.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI Medicines Compendium, 2015</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2016a</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018b</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018c</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] </p><!-- end field 629e5d51-1c9c-4017-8b4a-cbdfb4ac559c --><!-- end item e6ccbd5d-2727-4a58-b5d4-0845d2f90518 -->","subChapters":[]},{"id":"c6b4fed6-ee1c-5447-ba9a-1e3eca791d11","slug":"dose-of-long-acting","fullItemName":"Dose of long-acting","depth":3,"htmlHeader":"<!-- begin field 586c1348-e53c-40a8-862d-da358915a6e9 --><h3>Which long-acting beta-2 agonists are available for COPD, and what dose should I prescribe?</h3><!-- end field 586c1348-e53c-40a8-862d-da358915a6e9 -->","summary":"","htmlStringContent":"<!-- begin item 0a22714d-26fd-485d-a912-600fad8a1148 --><!-- begin field f1d17590-579d-4828-aa6a-93d27c55c839 --><ul><li><strong>Formoterol</strong><ul><li>Aerosol inhalation — 12 micrograms twice daily. Additional doses may be taken to a total maximum of 48 micrograms daily (maximum single dose is 24 micrograms).</li><li>Dry powder inhalation — 12 micrograms twice daily.</li></ul></li><li><strong>Salmeterol</strong><ul><li>By inhalation of aerosol, or inhalation of powder — 50 micrograms twice daily.</li></ul></li><li><strong>Indacaterol (Onbrez Breezhaler®)</strong><ul><li>Dry powder inhalation — 150 micrograms once daily, can be increased to 300 micrograms once daily.</li></ul></li><li><strong>Combination products</strong><ul><li><strong>Formoterol with aclidinium bromide</strong><ul><li>For maintenance treatment in COPD by inhalation of powder – 1 inhalation twice daily.</li></ul></li><li><strong>Formoterol with beclometasone</strong><ul><li>For COPD with FEV1 <50% predicted by inhalation of aerosol — 2 inhalations twice daily.</li><li>Fostair® is more potent than traditional beclometasone dipropionate CFC-free inhalers — dose of beclometasone dipropionate in Fostair® should be lower than non-extra-fine formulations and will need to be adjusted to the individual.</li></ul></li><li><strong>Formoterol with beclometasone and glycopyrronium</strong><ul><li>For moderate to severe COPD by inhalation of aerosol — 2 inhalations twice daily.</li></ul></li><li><strong>Formoterol with budesonide</strong><ul><li><strong>DuoResp Spiromax ® 160/4.5 </strong>— for COPD with FEV1 <70% of predicted — by inhalation of powder, 2 inhalations twice daily.</li><li><strong>Symbicort Turbohaler® 400/12</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, one puff twice daily.</li><li><strong>Fobumix ® 160/4.5 Easyhaler</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 2 inhalations twice daily.</li><li><strong>DuoResp Spiromax ® 320/9</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 1 inhalation twice daily.</li><li><strong>Fobumix ® 320/9 Easyhaler9</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 1 inhalation twice daily.</li><li><strong>Symbicort®200/6 pressurised inhaler — </strong>for COPD with FEV1 <70% of predicted — by inhalation of aerosol, 2 inhalations twice daily.</li><li><strong>Symbicort 200/6 Turbohaler®</strong> — for COPD with FEV1 <70% of predicted — by inhalation of powder, 2 puffs twice daily.</li><li>Other combinations of formoterol with budesonide are available but unlicensed for use in COPD.</li></ul></li><li><strong>Salmeterol with fluticasone</strong><ul><li><strong>Seretide 500 Accuhaler®</strong> (salmeterol 50 micrograms plus fluticasone propionate 500 micrograms) — one inhalation twice daily.</li><li><strong>AirFluSal Forspiro® </strong>— for COPD with FEV1 <60% of predicted by inhalation of powder, 1 inhalation twice daily.</li><li>Other combinations of salmeterol with fluticasone are available but are unlicensed for use in COPD.</li></ul></li><li><strong>Olodaterol</strong> is licensed for the maintenance treatment of COPD. However, it is a 'black triangle' drug subject to intense surveillance by the Medicines and Healthcare products Regulatory Agency (MHRA).</li></ul></li><li><strong>Recommended doses may vary for different brands available — doses for specific brands can be found in the BNF and the manufacturers' Summaries of Product Characteristics.</strong></li><li><strong>Clinicians should be aware of the increased risk of pneumonia associated with use of inhaled corticosteroids in people with COPD </strong>— for more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/prescribing-information/inhaled-corticosteroids/\">Inhaled steroids</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field f1d17590-579d-4828-aa6a-93d27c55c839 --><!-- end item 0a22714d-26fd-485d-a912-600fad8a1148 -->","subChapters":[]},{"id":"407ea797-3dc7-5e96-a00e-91bd84894d02","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field 6f674f9d-60cd-4ccf-a212-79d5ef3de5da --><h3>Cautions</h3><!-- end field 6f674f9d-60cd-4ccf-a212-79d5ef3de5da -->","summary":"","htmlStringContent":"<!-- begin item f95e3693-9e55-4316-8576-f2f462919ec8 --><!-- begin field 1c62d31d-978a-41e9-a56b-abfe04babb05 --><ul><li><strong>Beta-2 agonists should be used with caution in people with:</strong><ul><li>Hyperthyroidism — beta-2 agonists may stimulate thyroid activity.</li><li>Diabetes mellitus — there is a rare risk of hyperglycaemia and ketoacidosis (especially with intravenous use). Additional blood glucose measurements are recommended when treatment with a beta-2 agonist is commenced.</li><li>Cardiovascular disease (including hypertension, arrhythmias and hypertrophic obstructive cardiomyopathy) — beta-2 agonists may cause an increased risk of arrhythmias and significant changes to blood pressure and heart rate.</li><li>Susceptibility to QT-interval prolongation.</li><li>Hypokalaemia — plasma potassium concentration may be reduced by beta-2 agonists (particularly high doses).</li><li>Convulsive disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 1c62d31d-978a-41e9-a56b-abfe04babb05 --><!-- end item f95e3693-9e55-4316-8576-f2f462919ec8 -->","subChapters":[]},{"id":"88615d82-232a-5624-ae13-8b6690b7b8fb","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b957f470-de37-404f-a222-af1ba2533c09 --><h3>What are the adverse effects of beta-2 agonists?</h3><!-- end field b957f470-de37-404f-a222-af1ba2533c09 -->","summary":"","htmlStringContent":"<!-- begin item b4aed414-0f53-4f60-9613-d9c5b2a4ef09 --><!-- begin field fd26e76b-4baa-4822-9e3b-8c5fb53b472e --><ul><li><strong>The adverse effects of short-acting and long-acting beta-2 agonists are similar.</strong> They are usually dose related and include:<ul><li>Nervous system disorders such as tremor (occurs particularly in the hands and is usually worse in the first few days of treatment), headache, dizziness and seizures.</li><li>Cardiac disorders such as palpitations, arrhythmias, peripheral vasodilation and myocardial ischaemia.</li><li>Psychiatric disorders such as anxiety, restlessness and insomnia.</li><li>Metabolic and nutrition disorders such as:<ul><li>Hypokalaemia — potassium levels should be monitored in people on high doses of beta-2 agonists (for example people receiving parenteral and nebulized beta-2 agonists).</li><li>Hyperglycaemia.</li></ul></li><li>Gastrointestinal disorders such as nausea and taste alteration.</li><li>Respiratory disorders such as oropharyngeal irritation and paradoxical bronchospasm (rare).</li><li>Musculoskeletal disorders such as muscle cramps.</li></ul></li><li><strong>Ocular complications</strong> including acute angle-closure glaucoma and cataract have been reported in people using nebulized short-acting beta-2 agonists or combination products.<ul><li>Advise people using nebulized short-acting beta-2 agonists to use a mouthpiece rather than a mask to minimize exposure of the eyes to the drug.</li></ul></li><li>Risk of adverse events may be higher in people with a predisposition to arrhythmias and in people with pre-existing cardiovascular disease, or hypertension.</li><li>For some pressurised metered-dose inhalers there is a risk of airway obstruction from aspiration of loose objects.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">CSM, 1990</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field fd26e76b-4baa-4822-9e3b-8c5fb53b472e --><!-- end item b4aed414-0f53-4f60-9613-d9c5b2a4ef09 -->","subChapters":[]},{"id":"b17b9781-2071-50d1-ac0d-36d973e86962","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 57955bc9-f5a3-434e-b885-8a90e5b7520a --><h3>What drug interactions are important with beta-2 agonists?</h3><!-- end field 57955bc9-f5a3-434e-b885-8a90e5b7520a -->","summary":"","htmlStringContent":"<!-- begin item 9e1ffd5c-fe74-4e5e-b96b-0e876be76e9d --><!-- begin field e856e174-deb5-4449-a7ce-c7e1ec68d4bb --><ul><li>Corticosteroids, diuretics, and theophylline — monitor potassium levels.<ul><li>Beta-2 agonists can cause hypokalaemia (particularly at high doses), and this can be increased by other potassium-depleting drugs such as corticosteroids, loop diuretics, and theophylline, amiodarone, and SSRIs.</li></ul></li><li>Digoxin — monitor potassium levels and be alert to signs of digoxin toxicity, such as loss of appetite, nausea, vomiting, bradycardia, visual disturbance, and drowsiness.</li><li>Non-selective B-blocking drugs such as propranolol — manufacturer recommends avoid.</li><li>CYP3A4 inhibitors (such as ketoconazole) — may increase plasma levels of salmeterol and associated systemic effects.</li><li>For more information on drug interactions with beta-2 agonists, see the British National Formulary.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field e856e174-deb5-4449-a7ce-c7e1ec68d4bb --><!-- end item 9e1ffd5c-fe74-4e5e-b96b-0e876be76e9d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}